Department
ENT (Otolaryngology)
Sudden Hearing Loss, Tinnitus
1 FDA-approved
1 research
HBOT Applications
FDA-Approved Level B
Idiopathic Sudden Sensorineural Hearing Loss
FDA-approved adjunctive treatment (2011) when corticosteroid therapy fails. Reverses cochlear hypoxia and reduces endolymphatic hydrops, improving hearing recovery rates.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: UHMS / FDA-Approved
References: 9
Investigational / Preclinical Level C
Tinnitus
Investigational use for chronic tinnitus associated with cochlear hypoxia. Some clinical studies show improvement in tinnitus severity scores.
Protocol
Pressure
2.0 – 2.5 ATA
Duration
90 min
Sessions
10 – 20
Frequency
Once daily, 5×/week
Evidence basis: Clinical Research
References: 2